Literature DB >> 3101543

A general assay for UDPglucuronosyltransferase activity using polar amino-cyano stationary phase HPLC and UDP[U-14C]glucuronic acid.

M W Coughtrie, B Burchell, J R Bend.   

Abstract

The assay of UDPglucuronosyltransferase activity toward various substrates using UDP[U-14C]glucuronic acid is described. HPLC on a polar amino-cyano bonded phase column was used to separate radioactive glucuronides from unmetabolized UDP[U-14C]glucuronic acid and other labeled reaction products. Radioactivity was measured using flow-through scintillation counting. All the glucuronides analyzed, with one exception, chromatographed with the same retention time (9.0-9.6 min) under the conditions described. Glucuronide conjugates were identified by comparison with retention times of commercial glucuronide standards, using radioactive aglycones, or hydrolysis with beta-glucuronidase. The method provides a unified, sensitive (100-200 pmol of glucuronide product) and reproducible assay for a wide variety of UDPglucuronosyltransferase substrates, and could be extended to include many others.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3101543     DOI: 10.1016/0003-2697(86)90328-3

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  10 in total

1.  Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.

Authors:  Kathryn Kelly Erickson-Ridout; Junjia Zhu; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

2.  Further validation of the Mulder and van Doorn kinetic procedure for the measurement of microsomal UDP-glucuronosyltransferase activities.

Authors:  B Antoine; J A Boutin; G Siest
Journal:  Biochem J       Date:  1988-06-15       Impact factor: 3.857

3.  Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.

Authors:  Gang Chen; Nino E Giambrone; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2012-03       Impact factor: 2.089

4.  Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.

Authors:  Dongxiao Sun; Gang Chen; Ryan W Dellinger; Arun K Sharma; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

5.  Glucuronidation of tobacco-specific nitrosamines by UGT2B10.

Authors:  Gang Chen; Ryan W Dellinger; Dongxiao Sun; Thomas E Spratt; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2008-01-31       Impact factor: 3.922

6.  Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.

Authors:  Renee M Balliet; Gang Chen; Carla J Gallagher; Ryan W Dellinger; Dongxiao Sun; Philip Lazarus
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

7.  Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation.

Authors:  Joshua E Muscat; Gang Chen; Ashley Knipe; Steven D Stellman; Philip Lazarus; John P Richie
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

8.  Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.

Authors:  Kathryn K Erickson-Ridout; Dongxiao Sun; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

9.  Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.

Authors:  Dongxiao Sun; Gang Chen; Ryan W Dellinger; Kimberly Duncan; Jia-Long Fang; Philip Lazarus
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

10.  Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver.

Authors:  Aimee K Sutliff; Jian Shi; Christy J W Watson; Martina S Hunt; Gang Chen; Hao-Jie Zhu; Philip Lazarus
Journal:  Mol Pharmacol       Date:  2019-09-25       Impact factor: 4.436

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.